| Field | Specification |
|---|---|
| Mfr No | |
| Cas No. | |
| Clonality | |
| Expression System | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Taplitumomab (HV426036) is a research-grade recombinant antibody targeting CD19. Produced in mammalian cells with native-like glycosylation. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
- ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Specifications
| Host Species | Mouse |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG2a, kappa |
| Target | CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Expression System | Mammalian Cells |
| UniProt | P15391 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
B-lymphocyte antigen CD19 is a ~61 kDa protein. Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. CD19 is the therapeutic target of tafasitamab (Monjuvi).
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Vanshylla, K. et al. (2018) Scientific reports 8, 4244. PMID: 29523808
2. Carter, RH. et al. (1992) Science (New York, N.Y.) 256, 105-7. PMID: 1373518
3. van Zelm, MC. et al. (2006) The New England journal of medicine 354, 1901-12. PMID: 16672701
4. de Rie, MA. et al. (1989) Cellular immunology 118, 368-81. PMID: 2463100
5. Wang, Y. et al. (2002) Immunity 17, 501-14. PMID: 12387743
6. Sato, S. et al. (1997) Journal of immunology (Baltimore, Md. : 1950) 159, 3278-87. PMID: 9317126
7. Buhl, AM. et al. (1997) The Journal of experimental medicine 186, 1897-910. PMID: 9382888
